Akoya Biosciences
|
Year Established:
2017 |
|
|
Website:
akoyabio.com |
|
|
Company Type:
Small Business (1-10M TTM Revenue) |
Akoya Biosciences’ history represents the rapid advancement driving the field of multiplexed biomarker analysis and immunofluorescence tissue analysis. Today’s Akoya portfolio spans the spectrum from powerful tools for discovery of important biomarkers to clinical research applications.
Akoya Biosciences was founded in 2015 to commercialize the CODEX System to enable ultra-high multiplexing for biomarker discovery.
The Phenoptics™ technology was originally conceived and developed by Cambridge Research & Instrumentation, acquired by Caliper in 2010, and subsequently acquired by PerkinElmer in 2011. The Phenoptics™ technology was promptly adopted as the industry standard for multiplexed tissue analysis for translational and clinical research.
The partnership between PerkinElmer and Telegraph Hill Partners, announced in November of 2018, created the current Akoya Biosciences through the sale of Phenoptics by PerkinElmer and its incorporation into Akoya. This combined portfolio of complementary CODEX and Phenoptics technologies will continue to fuel groundbreaking advancements in cancer immunology, immunotherapy and a wide range of pathology research.
Akoya Biosciences currently offers Phenoptics multiplex IHC panel development and sample staining and analysis as a service through its Contract Research Services (CRS) group.
Media
| Site | Badges | |
|---|---|---|
| Akoya Menlo Park 1080 O'Brien Drive Menlo Park, CA, 94025 United States | ||
| Akoya Biosciences, Inc., CRS 100 Campus Drive Marlboro, MA, 01752 United States | ||
Get started
If your organization has a Scientist.com marketplace, you can log in here to order products and services directly. If you're interested in ordering custom research services from suppliers in the Scientist.com network, book a meeting with our team here. To order products instantly, request access below.